Abilify Tapering Guide
aripiprazole
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis. Suicidality risk in children, adolescents, and young adults (for MDD adjunct indication).
Overview
Aripiprazole is an atypical antipsychotic with a unique mechanism as a partial agonist at dopamine D2 receptors. It is approved for schizophrenia, bipolar I disorder, adjunctive treatment of MDD, irritability in autism, and Tourette disorder.
2mg, 5mg, 10mg, 15mg, 20mg, 30mg
Tablets: 2mg, 5mg, 10mg, 15mg, 20mg, 30mg; Orally disintegrating tablets: 10mg, 15mg; Oral solution: 1mg/mL; Intramuscular injection: 9.75mg/1.3mL; Extended-release injection (Abilify Maintena): 300mg, 400mg
Category C (risk cannot be ruled out)
Mechanism of Action
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and antagonist at serotonin 5-HT2A receptors. This unique "dopamine stabilizer" profile means it can act as a functional antagonist in hyperdopaminergic states and a functional agonist in hypodopaminergic states.
Taper Notes
Very long half-life. Liquid formulation (1mg/mL) available. Often used as adjunct to antidepressants.
Hyperbolic Tapering Guidance
Long half-life provides some buffering. Oral solution (1mg/mL) allows precise reductions. Reduce gradually despite long half-life.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- CYP2D6 inhibitors (fluoxetine, paroxetine) increase aripiprazole levels — reduce aripiprazole dose by 50%
- CYP3A4 inhibitors (ketoconazole, itraconazole) increase aripiprazole levels — reduce dose by 50%
- CYP3A4 inducers (carbamazepine, rifampin) decrease aripiprazole levels — double dose when co-administered
Food Interactions
- Food does not affect absorption
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to aripiprazole
Toxicity
Akathisia is the most common dose-limiting side effect. Less metabolic burden than other atypicals (lower weight gain, lipid changes). Compulsive behaviors (gambling, eating, shopping) reported. NMS and tardive dyskinesia rare.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~87%. Tmax 3–5 hours. Food does not significantly affect absorption.
~4.9 L/kg
Hepatic via CYP3A4 and CYP2D6 to the active metabolite dehydro-aripiprazole, which has similar D2 receptor affinity. Dehydro-aripiprazole represents ~40% of parent drug AUC in plasma.
Fecal (~55%) and renal (~25%). Less than 1% excreted unchanged in urine.
>99% (primarily albumin)
~3.5 mL/min/kg
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Abilify (aripiprazole) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.